Find a Tender
complete
Official procurement procedure
Tocilizumab Subcutaneous Injection (RoActemra®)
Pharmaceutical products
Published value
Not published
Submission deadline Not published
Lots published1
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS"): "Tocilizumab Subcutaneous Injection (RoActemra®)". Published status: complete. Published value: Value not published. 1 published lot. Submission deadline not published. See the official notice for participation instructions.
| Contracting Authority | The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS") | Scope & Categories | Not published | Submission Window | complete No deadline published |
|---|---|---|---|---|---|
| Submission Gateway | Direct notice route | Legal Basis & Regime | Standard procurement | Estimated Value (exc. VAT) | Not published |
Bidder Intelligence · Authority Profile: The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")
Market Analytics
Derived from OCDS awards & bid statistics
Published history for The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS"). These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Published-to-award variance
Not availableInsufficient comparable data
Competition Density
9.9Bids / Report
Supplier ConcentrationNo estimate
Insufficient attributable awardsNo concentration estimate availablePayment Terms
Check noticePublished terms
Coverage: 974 active published awards; 798 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Published-to-award variance compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Procedure terms
Procedure methodNot published | Procurement categoryNot published | |
Statuscomplete | Framework / DPSFramework | CompetitionNot published |
Above thresholdNot published | Legal basisNot published | Tender period startsNot published |
Clarification deadlineNot published | Electronic submissionNot published | Submission languagesNot published |
Published3 Feb 2021, 10:24 GMT | Last source update3 Feb 2021, 10:24 GMT | Recurring procurementNot published |
ClassificationPharmaceutical products | ||
Delivery area | ||
OCIDocds-h6vhtk-028fa5 | ||
What is being bought
The supply of Tocilizumab Subcutaneous Injections (RoActemra®) to NHS Scotland which used to treat licensed indications. This medicine is not being procured to treat Covid-19.
What changed
From the official release history
- Status changed to complete
3 Feb 2021, 10:24 GMT - Official notice release published
3 Feb 2021, 10:24 GMT - Buyer information updated
3 Feb 2021, 10:24 GMT
Lots and requirements (1)
Published by the contracting authority
- Lot 1 · #1Individual lot title not publishedcancelledPublished valueNot publishedSupply of Tocilizumab Subcutaneous Injections (RoActemra®) to NHS Scotland. The Authority has awarded this framework as a single supplier framework per line.Contract periodNot publishedEligibilityNot publishedOptions / renewalNot published
Timeline
- Procedure published
3 Feb 2021, 10:24 GMT - Award active
Not published · Not published - Contract active
Signed 10 Dec 2020, 00:00 GMT · £25,050,684
Commercial outcome and competition
Awards Roche Products Ltd Not published · Not published · active |
Contracts Contract £25,050,684 · signed 10 Dec 2020, 00:00 GMT · active |
Bid statistics bids: 1 (lot 1) electronicBids: 1 (lot 1) foreignBidsFromEU: 0 (lot 1) foreignBidsFromNonEU: 1 (lot 1) smeBids: 0 (lot 1) |
Buyer and organisations in this procedure
The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")
Contracting authority GB-FTS-322Documents (0)
Official links; attachments are not copied
No linked documents are published
Related procedures (0)
No related procedures published
Planning and rationale
Planning budgetNot published |
No-engagement rationaleNot published |
Procedure rationaleThe patent for Tocilizumab (RoActemra®) has expired December 2020, there is no known competition that has entered the UK market place and there is none anticipated for the initial duration of the framework agreement. |